Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 26,684 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Stiff Person Syndrome
Interventions: VYVGART Hytrulo, Hytrulo-placebo (consisting of Hyaluronidase); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 25 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, Medication Adherence
Interventions: SteadyRx; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: Placebo, bitopertin [RO4917838]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Carson, California • Oceanside, California • San Diego, California + 17 more

Conditions: Dementia, Alzheimer Disease, Caregiver Burden, Self Efficacy
Interventions: Learning Skills Together Intervention, Caregiver Healthy Living Intervention; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anxiety, Stress
Interventions: Slow diaphragmatic breathing; Behavioral
Lead sponsor: Health and Human Performance Foundation; Other
Eligibility: 16 Years to 19 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Aspen, Colorado

Conditions: Proliferative Diabetic Retinopathy
Interventions: emixustat hydrochloride, Placebo; Drug · Other
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Arcadia, California

Conditions: Dry Eye Disease (DED)
Interventions: OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray; Drug
Lead sponsor: Oyster Point Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 22
States / cities: Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more

Conditions: Fibrocystic Breast Condition (FBC)
Interventions: Violet™ Molecular Iodine (I2), Placebo; Dietary Supplement · Other
Lead sponsor: BioPharmX, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Marijuana Use
Interventions: 1) Face-to-face, and 2) Computer-mediated motivational type interviews; Behavioral
Lead sponsor: University of Texas, El Paso; Other
Eligibility: 18 Years to 29 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Unauthorized Data Access
Interventions: receiving an email; Other
Lead sponsor: Protenus, Inc.; Industry
Eligibility: Not listed
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Gout
Interventions: RDEA3170 and Placebo; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Thrombosis
Interventions: Rivaroxaban, Acetylsalicylic Acid; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 8 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 17
States / cities: Los Angeles, California • Gainesville, Florida • Oak Lawn, Illinois + 14 more

Conditions: Healthy Subjects
Interventions: AZD1979, Placebo to match; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hematological Malignancies
Interventions: Ibandronate, Vitamin Supplements; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine Headache
Interventions: Galcanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 40
States / cities: Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more

Conditions: Pneumonia
Interventions: Auxora (Part 1), Standard of Care (Part 1), Auxora (Part 2), Placebo (Part 2); Drug
Lead sponsor: CalciMedica, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 17
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Dementia, Alzheimer Disease, Caregiver Stress
Interventions: Structured Retrieval Practice, Reading-Based Education; Behavioral
Lead sponsor: Virginia Wesleyan University; Other
Eligibility: 50 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Conditions: Respiratory Tract Infection
Interventions: RSVpreF, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Years to 49 Years · Female only
Enrollment: 14,727 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 363
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 137 more

Conditions: Delayed Graft Function
Interventions: ANG-3777, Placebo; Drug · Other
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Horizons International Peripheral Group; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Fairhope, Alabama • Houma, Louisiana • Lafayette, Louisiana

Conditions: Ejaculation
Interventions: Treatment sequence 2, Treatment sequence 1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more

Conditions: Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions: CNP-103, Placebo; Drug
Lead sponsor: COUR Pharmaceutical Development Company, Inc.; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 45
States / cities: Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more

Conditions: Schizophrenia
Interventions: PF 03654746, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 40 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tourette Syndrome
Interventions: pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID, pramipexole 0.25 mg BID, pramipexole 0.0625 mg BID; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more

Search by objective public record fields.

VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)

SteadyRx: Smartphone ART Adherence Intervention for Drug Users

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Learning Skills Together Family Caregiver Complex Intervention

Breathing for Adolescent Stress Reduction Feasibility RCT

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

Computer-Mediated Versus Face-to-Face Motivational-Type Interviews

The Effectiveness of Email Alerting on Reducing Employees' Unauthorized Access to Protected Health Information

Single and Multiple Dose Study in Japanese Subjects

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache

A Study of Auxora in Patients With Severe COVID-19 Pneumonia

Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

Add On Treatment for Cognitive Deficits in Schizophrenia

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome